Terms: = Lymphoma AND SYK, P43405, 6850, ENSG00000165025
280 results:
1. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
2. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract] [Full Text] [Related]
3. Dynamic hydrogen peroxide levels reveal a rate-dependent sensitivity in B-cell lymphoma signaling.
Witmond M; Keizer E; Kiffen B; Huck WTS; van Buggenum JAGL
Sci Rep; 2024 Feb; 14(1):4265. PubMed ID: 38383739
[TBL] [Abstract] [Full Text] [Related]
4. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available syk Inhibitor.
Cai Y; He J; Wu Z; He W; Dai X; Xu Y; Cheng M; Yang N; Ren Y; Wang G; Wang J; Sai Y; Jia H; Dai G; Li X; Su W
J Pharmacol Exp Ther; 2024 Jan; 388(1):156-170. PubMed ID: 37918855
[TBL] [Abstract] [Full Text] [Related]
5. Luxeptinib interferes with LYN-mediated activation of syk and modulates BCR signaling in lymphoma.
Sonowal H; Rice WG; Howell SB
PLoS One; 2023; 18(3):e0277003. PubMed ID: 36888611
[TBL] [Abstract] [Full Text] [Related]
6. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Gordon LI; Karmali R; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau FI; Radford J; de Oteyza JP; Zinzani PL; Iyer SP; Townsend W; Miao H; Proscurshim I; Wang S; Katyayan S; Yuan Y; Zhu J; Stumpo K; Shou Y; Carpio C; Bosch F
Oncotarget; 2023 Jan; 14():57-70. PubMed ID: 36702329
[TBL] [Abstract] [Full Text] [Related]
7. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract] [Full Text] [Related]
8. ArtinM Cytotoxicity in B Cells Derived from Non-Hodgkin's lymphoma Depends on syk and Src Family Kinases.
Barboza BR; Thomaz SMO; Junior AC; Espreafico EM; Miyamoto JG; Tashima AK; Camacho MF; Zelanis A; Roque-Barreira MC; da Silva TA
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674590
[TBL] [Abstract] [Full Text] [Related]
9. Recent advances in understanding spleen tyrosine kinase (syk) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract] [Full Text] [Related]
10. Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies.
Li C; Watson K; Wang S; Diderichsen PM; Gupta N
J Clin Pharmacol; 2023 Mar; 63(3):326-337. PubMed ID: 36309821
[TBL] [Abstract] [Full Text] [Related]
11. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract] [Full Text] [Related]
12. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
Ikeda M; Hayes CK; Schaller SJ; Longnecker R
Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
[TBL] [Abstract] [Full Text] [Related]
13. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
[TBL] [Abstract] [Full Text] [Related]
14. USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.
Wu Y; Gu H; Bao Y; Lin T; Wang Z; Gu D; Shen H; Xian H; Fan Y; Mao R
Cell Biochem Funct; 2022 Jun; 40(4):379-390. PubMed ID: 35411950
[TBL] [Abstract] [Full Text] [Related]
15. syk and ZAP70 kinases in autoimmunity and lymphoid malignancies.
Leveille E; Chan LN; Mirza AS; Kume K; Müschen M
Cell Signal; 2022 Jun; 94():110331. PubMed ID: 35398488
[TBL] [Abstract] [Full Text] [Related]
16. Dual BTK/syk inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
[TBL] [Abstract] [Full Text] [Related]
17. A new role for the SRC family kinase HCK as a driver of syk activation in MYD88 mutated lymphomas.
Munshi M; Liu X; Kofides A; Tsakmaklis N; Guerrera ML; Hunter ZR; Palomba ML; Argyropoulos KV; Patterson CJ; Canning AG; Meid K; Gustine J; Branagan AR; Flynn CA; Sarosiek S; Castillo JJ; Wang J; Buhrlage SJ; Gray NS; Munshi NC; Anderson KC; Treon SP; Yang G
Blood Adv; 2022 Jun; 6(11):3332-3338. PubMed ID: 35255496
[TBL] [Abstract] [Full Text] [Related]
18. Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell lymphoma.
Devin J; Cañeque T; Lin YL; Mondoulet L; Veyrune JL; Abouladze M; Garcia De Paco E; Karmous Gadacha O; Cartron G; Pasero P; Bret C; Rodriguez R; Moreaux J
Cancer Res; 2022 Mar; 82(6):998-1012. PubMed ID: 35078814
[TBL] [Abstract] [Full Text] [Related]
19. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
[TBL] [Abstract] [Full Text] [Related]
20. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
Li C; Li W; Xu G; You M; Wu W; Kuang L
Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
[TBL] [Abstract] [Full Text] [Related]
[Next]